Introducing...MAN BluePrint!
Contains The Revolutionary New Breakthrough Compound - Agmatine!
Blueprint™ features what may very well be The Holy Grail of Supplements™ Agmatine. As a metabolic byproduct of Arginine, Agmatine goes beyond Arginine and works its wonders by stimulating the release of pituitary hormones such as Leutinizing Hormone (LH) and Growth Hormone (GH). Agmatine also demonstrates insulin like properties.
Other proposed roles of Agmatine are in cardiovascular biology as it can modulate heart; brain and vasculature function via its effects on calcium homeostasis as well as modulating the synthesis of NO. Agmatine is neuroproective and is an intermediate in polyamine biosynthesis. All of this, giving Agmatine legitimate stake as the true Holy Grail of Supplements!
Blueprint™ also integrates R-ALA (r-alpha-lipoic-acid) with Agmatine because it is one of the best and most complete antioxidants known to MAN and it is also a very effective supplement for improving insulin response/sensitivity, making it an ideal compliment to the anabolic and ergogenic effects of Agmatine.
Product Highlights:
Contains 300 mg of R-ALA per serving.
Stimulates The Release of Pituitary Peptide Hormones, LH and GH!
Supports an Anabolic Environment.
Improves Insulin Response and Sensitivity.
Prevents Free Radical Damage.
Modulates Nitric Oxide.
Increases Muscle Fullness.
For a more fit body, fuller muscles and greater strength and performance, "Set It Off" with Blueprint™.
Blueprint™ can be combined with Clout™ and Body Octane™ for individuals looking to maximize performance, lean body mass and recovery from exercise. Blueprint™ can also be combined with Vaporize™ for overall health and Scorch™ to maintain and anabolic environment while trying to reduce bodyfat.
Scientific References: Kalra, S.P., et al. Agmatine, a novel hypothalamic amine, stimulates pituitary luteinizing hormone release in vivo and hypothalamic luteinizing hormone-releasing in vivo. Neuroscience Letters. 194 (3): July 21, 1995; 165-168.
Reis, D.J. and S. Regunathan. Agmatine a novel neurotransmitter? Advances in Pharmacology. 42:645-649, 1998.
Sener, A., et al. Stimulus-secretion coupling of arginine-induced insulin release. Insulinotropic action of agmatine. Biochemical Pharmacology. January 15, 1989. 38(2):327-330.
Weitzel G., et al. Insulin-like partial effects of agmatine derivatives in adipocytes. Hoppe-Seylers Zeitschrift fur Physiologische Chemie. January 1980; 361(1):51-60.
Morgan, N.G., et al. Characterization of the imidazoline binding site in regulation of insulin secretion. Annals of the New York Academy of Sciences. July 12, 1995. 763:361-373.
Yananli H, Goren MZ, Berkman K, Aricioglu F. Effect of agmatine on brain l-citrulline production during morphine withdrawal in rats: A microdialysis study in nucleus accumbens. Brain Res. 2007 Feb 9;1132(1):51-58. Epub 2006 Dec 19.
Gao, Y., et al. Agmatine: a novel vasodilator substance. Life Sciences. 1995. 57(8):PL83-86.
Lortie, M.J., et al. Agmatine, a bioactive metabolite of arginine. Production, degradation, and functional effects in the kidney of the rat. Journal of Clinical Investigation. January 15, 1996; 97(2):413-420.
Raasch, W. et al. Agmatine, the bacterial amine is widely distributed in mammalian tissues. Life Sciences. 1995. 56(26):2319-2330.
Halaris A, Piletz JE. Imidazoline receptors: possible involvement in the... Hum Psychopharmacol. 2001 Jan;16(1):65-69.
Raghavan SA, Dikshit M. Vascular regulation by the L-arginine metabolites, nitric oxide and agmatine. Pharmacol Res. 2004 May;49(5):397-414. Review.
Zarandi M, Serfozo P, Zsigo J, Deutch AH, Janaky T, Olsen DB, Bajusz S, Schally AV. Potent agonists of growth hormone-releasing hormone. II. Pept Res. 1992 Jul-Aug;5(4):190-3. |
Submit Your Product Review!
